152 related articles for article (PubMed ID: 12043198)
1. [Results of clinical studies on a selective inhibitor of ABL tyrosine kinase (STI571) in patients with Ph(+) leukemia].
Ohnisi K
Rinsho Ketsueki; 2002 Apr; 43(4):235-8. PubMed ID: 12043198
[No Abstract] [Full Text] [Related]
2. Current treatment approaches for chronic myelogenous leukemia.
Druker BJ
Cancer J; 2001; 7 Suppl 1():S14-8. PubMed ID: 11504279
[TBL] [Abstract][Full Text] [Related]
3. Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer.
Shah NP; Sawyers CL
Curr Opin Investig Drugs; 2001 Mar; 2(3):422-3. PubMed ID: 11575716
[No Abstract] [Full Text] [Related]
4. [Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].
Hochhaus A
Dtsch Med Wochenschr; 2002 Mar; 127(9):451-6. PubMed ID: 11870560
[No Abstract] [Full Text] [Related]
5. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
Druker BJ
Oncogene; 2002 Dec; 21(56):8541-6. PubMed ID: 12476300
[No Abstract] [Full Text] [Related]
6. [Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].
Molnár L; Losonczy H
Orv Hetil; 2002 Oct; 143(42):2379-84. PubMed ID: 12440260
[TBL] [Abstract][Full Text] [Related]
7. [Tyrosine kinase inhibitor--hematological malignancies].
Ohno R
Gan To Kagaku Ryoho; 2001 May; 28(5):601-7. PubMed ID: 11383207
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of chronic myelogenous leukemia with tyrosine kinase inhibitor].
Ohno R
Nihon Rinsho; 2001 Dec; 59(12):2389-94. PubMed ID: 11766344
[TBL] [Abstract][Full Text] [Related]
9. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Goldman JM; Melo JV
N Engl J Med; 2001 Apr; 344(14):1084-6. PubMed ID: 11287980
[No Abstract] [Full Text] [Related]
10. [Chronic myeloid leukemia and imatinib mesylate therapy].
Chrobák L
Vnitr Lek; 2004 Jan; 50(1):10-2. PubMed ID: 15015223
[No Abstract] [Full Text] [Related]
11. Imatinib and chronic-phase leukemias.
Boros LG; Lee WN; Cascante M
N Engl J Med; 2002 Jul; 347(1):67-8. PubMed ID: 12097546
[No Abstract] [Full Text] [Related]
12. [A new drug in the therapy of chronic myeloid leukemia: ST1571].
Salesi N; Bossone G; Della Longa G; Di Cocco B
Minerva Med; 2003 Apr; 94(2):71-6. PubMed ID: 12858155
[TBL] [Abstract][Full Text] [Related]
13. Use of imatinib mesylate in a 15-month old with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia.
Richardson MW; Grewal SS
Pediatr Blood Cancer; 2008 Jan; 50(1):186. PubMed ID: 17455313
[No Abstract] [Full Text] [Related]
14. CML: imatinib mesylate (Glivec) or something else?
Ghosh A
Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
[No Abstract] [Full Text] [Related]
15. [Anti-tyrosine kinase: the beginning of molecular therapies of cancer and initial results].
Guilhot F
Bull Cancer; 2001 Jul; 88(7):659-60. PubMed ID: 11495817
[No Abstract] [Full Text] [Related]
16. [STI571: a new dimension in the treatment of chronic myeloid leukemia].
Somers JA; Shamelian SO; Löwenberg B; Ossenkoppele GJ; Cornelissen JJ
Ned Tijdschr Geneeskd; 2002 Jan; 146(3):128-32. PubMed ID: 11826673
[TBL] [Abstract][Full Text] [Related]
17. [Molecular-target therapy of Ph-positive leukemia by imatinib (tyrosine kinase inhibitor)].
Tauchi T; Ohyashiki K
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1065-70. PubMed ID: 12938259
[TBL] [Abstract][Full Text] [Related]
18. Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line.
Rabizadeh E; Merkin V; Belyaeva I; Shaklai M; Zimra Y
Leuk Res; 2007 Aug; 31(8):1115-23. PubMed ID: 17267032
[TBL] [Abstract][Full Text] [Related]
19. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.
Druker BJ; Lydon NB
J Clin Invest; 2000 Jan; 105(1):3-7. PubMed ID: 10619854
[No Abstract] [Full Text] [Related]
20. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]